Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 50, Issue 2, Pages 239-249Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.108.056655
Keywords
response assessment; surrogate biomarker; functional/molecular imaging; volumetric CT; lung cancer
Ask authors/readers for more resources
This article addresses the current status of quantitative imaging as a surrogate biomarker for the assessment of tumor response to therapy with non-small cell lung cancer as an example. In addition, the article discusses the limitations of conventional response criteria in the new era of molecular-targeted agent for cancer treatment; the increasing need for more accurate and early response-assessment methods, particularly for volumetric CT; new tumor-specific radiotracers and molecular imaging technologies; and the future applications of molecular imaging with PET for studying various features of cancer metabolism, endocrine status, hypoxia, and oncofetal and differentiation antigens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available